Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

New 800-mg Prezista

January/February 2013

Photo courtesy of Janssen Pharmaceuticals.

Photo courtesy of Janssen Pharmaceuticals.

The long-awaited 800-mg Prezista tablet has been approved by the FDA. Previously, people on Prezista took two 400-mg tablets once a day (with Norvir). Prezista must still be taken with Norvir and food, but now only one pill once a day. Kudos to Janssen Pharmaceuticals for reducing pill burden for Prezista patients.

Janssen plans to phase out the 400-mg pills. Still in the works is a co-formulated pill with a drug level booster built right in, combining Prezista with the PK (pharmacokinetic) enhancer cobicistat. This would eliminate the need for taking Norvir. Cobicistat by itself is not yet on the market, but is part of the recently FDA approved single tablet regimen Stribild.

The new tablet will be covered by the Janssen Patient Savings Program and the Johnson & Johnson Patient Assistance Foundation.


Got a comment on this article? Write to us at publications@tpan.com.


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by Positively Aware. It is a part of the publication Positively Aware. Visit Positively Aware's website to find out more about the publication.
 
See Also
More on HIV Medications
More News on Darunavir (Prezista)

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement